Faulkner Michele A, Lenz Tom L, Stading Julie A
Creighton University School of Pharmacy and Health Professions, 2500 California Plaza, Omaha, NE 68178, USA.
Int J Chron Obstruct Pulmon Dis. 2006;1(3):279-87. doi: 10.2147/copd.2006.1.3.279.
The cost burden of COPD is substantial for patients and families, payers, and society as a whole. Smoking has been known for decades to be the leading cause of the disease. Numerous studies have been completed to address the cost-effectiveness of programs created to aid smokers in their efforts to quit. Because several assumptions must be made in order to conduct such a study, and because differences in study design are numerous, comparison of data is difficult. However, studies have consistently shown that regardless of the perspective from which the study was completed, or the methods used to help smokers abstain, the interventions are cost-effective. Although no study has been conducted specifically to assess the cost-effectiveness of smoking cessation interventions as they relate directly to patients with COPD, based on current data it can be concluded that smoking cessation programs are cost-effective for this population.
慢性阻塞性肺疾病（COPD）给患者及其家庭、付款方乃至整个社会都带来了沉重的经济负担。数十年来，吸烟一直被认为是该疾病的主要病因。为了评估帮助吸烟者戒烟项目的成本效益，人们已经完成了大量研究。由于进行此类研究必须做出若干假设，且研究设计存在诸多差异，因此数据比较困难。然而，研究一直表明，无论研究是从何种角度完成的，也无论采用何种方法帮助吸烟者戒烟，这些干预措施都具有成本效益。尽管尚未专门开展研究来评估与COPD患者直接相关的戒烟干预措施的成本效益，但根据现有数据可以得出结论，戒烟项目对这一人群具有成本效益。
